Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17189653 | 0.80 | LMNA (0.34) | LMNASMN1; SMN2NPSR1 | |
| SCHEMBL3714980 | 0.74 | LMNA (0.41) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL21798037 | 0.73 | CYP3A4 (0.40) | LMNASMN1; SMN2NPSR1 | |
| SCHEMBL25349015 | 0.73 | LMNA (0.43) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL19537486 | 0.70 | NPSR1 (0.36) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL23675613 | 0.69 | LMNA (0.46) | LMNASMN1; SMN2 | |
| SCHEMBL25048934 | 0.65 | LMNA (0.42) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL16369615 | 0.64 | LMNA (0.34) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL21598377 | 0.63 | NPSR1 (0.43) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL4822241 | 0.63 | NPSR1 (0.39) | LMNASMN1; SMN2FFAR3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| EP-2729447-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013007621-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2013-01-17 | — | — | WO | disclosed |
| EP-2222655-A1 | N-CYCL0ALKYLMETHYL-2-AMIN0THIAZ0LE-5-CARB0XAMIDES FOR USE IN PLANT DISEASE CONTROL | Sumitomo Chemical Company, Limited (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-2144898-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009066790-A1 | N-CYCL0ALKYLMETHYL-2-AMIN0THIAZ0LE-5-CARB0XAMIDES FOR USE IN PLANT DISEASE CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
| EP-2048953-A2 | INSECTICIDAL COMPOSITION | Livie Biopesticides Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008130021-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008035029-A2 | INSECTICIDAL COMPOSITION | LIVIE BIOPESTICIDES LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
| WO-2001000581-A1 | LIGANDS BASED ON CHIRAL 2-AMINO-2'-HYDROXY-1,1'-BINAPHTHYL AND RELATED FRAMEWORKS FOR ASYMMETRIC CATALYSIS | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | LMNA 3435/4885SMN1; SMN2 1995/4885FFAR3 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.